Abstract
Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Adult
-
Aged
-
Aged, 80 and over
-
Albumins / administration & dosage
-
Albumins / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Clinical Trials, Phase III as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Drug Administration Schedule
-
Fatigue / chemically induced
-
Gemcitabine
-
Humans
-
Middle Aged
-
Neoplasm Metastasis
-
Neutropenia / chemically induced
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Randomized Controlled Trials as Topic
-
Survival Analysis
-
Treatment Outcome
Substances
-
130-nm albumin-bound paclitaxel
-
Albumins
-
Deoxycytidine
-
Paclitaxel
-
Gemcitabine